EOLS (Evolus) Float Percentage Of Total Shares Outstanding : 97.89% (As of May. 04, 2025)

View and export this data going back to 2018. Start your Free Trial

What is Evolus Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Evolus's float shares is 62.25 Mil. Evolus's total shares outstanding is 63.59 Mil. Evolus's float percentage of total shares outstanding is 97.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Evolus's Insider Ownership is 3.65%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Evolus's Institutional Ownership is 82.02%.

Evolus Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Evolus's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	62.25	/	63.59
	=	97.89%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

EVL:Germany

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Executives

David Moatazedi	director, officer: See Remarks	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Tomoko Yamagishi-dressler	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Sandra Beaver	officer: Chief Financial Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar	officer: See Remarks	1618 STATION STREET, VANCOUVER A1 V6A 1B6
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949
Vikram Malik	director	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Medytox Inc.	10 percent owner	78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Alphaeon 1 Llc	10 percent owner	4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman	director	8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank	director	C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail	officer: See Remarks	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Crystal Muilenburg	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart	director	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660